{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:49:44Z","timestamp":1793875784228,"version":"4.7.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center & Research Institute- Library","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014228","name":"Duke Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijgc.2025.102856","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:12:32Z","timestamp":1765642352000},"page":"102856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6156-8885","authenticated-orcid":false,"given":"Robert M.","family":"Wenham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-2798","authenticated-orcid":false,"given":"Andrea L.","family":"Buras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0443-5573","authenticated-orcid":false,"given":"Sarah W.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-7956","authenticated-orcid":false,"given":"Brooke L.","family":"Fridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin M.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian M.","family":"Shahzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany A.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-7662","authenticated-orcid":false,"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ijgc.2025.102856_bib1","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ijgc.2025.102856_bib2","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III Aurelia trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102856_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102856_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"34","key":"10.1016\/j.ijgc.2025.102856_bib5","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.ijgc.2025.102856_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","article-title":"Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced\/recurrent ovarian and uterine cancers","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102856_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102856_bib8","article-title":"NCCN Guidelines- Ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer","year":"2025","journal-title":"National Comprehensive Cancer Network"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102856_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2025.102856_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell Mol Biol Lett"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102856_bib11","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ijgc.2025.102856_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-3083.2011.02514.x","article-title":"CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4","volume":"73","author":"Zhu","year":"2011","journal-title":"Scand J Immunol."},{"issue":"4","key":"10.1016\/j.ijgc.2025.102856_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejps.2009.08.009","article-title":"Paclitaxel and immune system","volume":"38","author":"Javeed","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102856_bib14","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N","article-title":"The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol","volume":"31","author":"Byrd-Leifer","year":"2001","journal-title":"Eur J Immunol"},{"issue":"5-6","key":"10.1016\/j.ijgc.2025.102856_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1081\/CNV-120003535","article-title":"Premedication strategy for weekly paclitaxel","volume":"20","author":"Quock","year":"2002","journal-title":"Cancer Invest"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102856_bib16","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102856_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2025.102856_bib18","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102856_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in ovarian cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch Immunol Ther Exp (Warsz)."},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102856_bib20","article-title":"Immunotherapy with anti-PD-1 or PD-L1 in advanced ovarian cancer (OC): a meta-analysis of randomized trials","volume":"43","author":"Vida","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2025.102856_bib21","volume":"41","author":"Harter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102856_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer.: results from the randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102856_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2019.04.043","article-title":"Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer","volume":"154","author":"Walsh","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102856_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2025.102856_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102856_bib36","doi-asserted-by":"crossref","first-page":"102732","DOI":"10.1016\/j.ijgc.2025.102732","article-title":"Pembrolizumab vs Placebo Plus Weekly Paclitaxel With or Without Bevacizumab for Platinum-Resistant Ovarian Cancer: Results from the Randomized, Double-Blind Phase 3 ENGOT-ov65\/KEYNOTE-B96 Study","volume":"35","author":"Colombo","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102856_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2025.102856_bib27","series-title":"asoMC","author":"Sharp","year":"2020"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102856_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/imt-2016-0134","article-title":"Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab","volume":"9","author":"Rassy","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijgc.2025.102856_bib29","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","article-title":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma","volume":"16","author":"Bickel","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102856_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102856_bib31","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.3390\/cancers13174438","article-title":"Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives","volume":"13","author":"Maiorano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102856_bib32","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.31557\/APJCP.2019.20.4.1161","article-title":"Programmed death ligand 1 (PD-L1) expression in epithelial ovarian cancer: a comparison of type I and Type II tumors","volume":"20","author":"Nhokaew","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102856_bib33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 17","key":"10.1016\/j.ijgc.2025.102856_bib34","article-title":"ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)","volume":"43","author":"Olawaiye","year":"2025","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102856_bib35","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.18632\/oncotarget.27989","article-title":"Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells","volume":"12","author":"Greenstein","year":"2021","journal-title":"Oncotarget"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:33:47Z","timestamp":1780306427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1048891X25019802"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102856","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102856"}}